CN1708237A - Composition for enhancing physical performance - Google Patents

Composition for enhancing physical performance Download PDF

Info

Publication number
CN1708237A
CN1708237A CNA2003801021039A CN200380102103A CN1708237A CN 1708237 A CN1708237 A CN 1708237A CN A2003801021039 A CNA2003801021039 A CN A2003801021039A CN 200380102103 A CN200380102103 A CN 200380102103A CN 1708237 A CN1708237 A CN 1708237A
Authority
CN
China
Prior art keywords
composition
vitamin
epicatechin
tea
further comprise
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2003801021039A
Other languages
Chinese (zh)
Inventor
托马斯·克里斯琴·莱恩斯
小野光则
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quercegen Holdings LLC
Original Assignee
Quercegen Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quercegen Holdings LLC filed Critical Quercegen Holdings LLC
Publication of CN1708237A publication Critical patent/CN1708237A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

A composition that contains (1) quercetin and vitamin B3, or (2) quercetin and vitamin C. The invention also discloses a method of using the composition for enhancing physical performance.

Description

Be used to strengthen the composition of physical efficiency
The cross reference of related application
The application is in the extendible portion of the 10/302nd, No. 544 U.S. Patent application of submission on November 22nd, 2002, and this application requires again in the priority of the 60/420th, No. 986 U. S. application of submission on October 23rd, 2002.
Technical field
The present invention relates to a kind of composition and a kind of method of using foregoing with the enhancing physical efficiency that is used to strengthen physical efficiency.
Background technology
For a long time, the summit that reaches physical efficiency is the target of agonistic sports and self-improvement always.The method of improving physical efficiency comprises the exercise of long-term system, reasonable diet and uses medicine such as anabolic steroid.Anabolic steroid is a kind of testosterone derivative, and it can promote organizational growth, increases muscle quality, blood flow volume and hemoglobin level, and improves overall strength.But, use anabolic steroid often to cause severe complications, as reducing blood middle-high density lipoprotein levels, reproductive system disorder or causing the liver disease to comprise liver cancer or hepatic peliosis.These complication further cause women's manlike, interruption child to grow up or cause the fetus defective.Use anabolic steroid also can cause mental disease, as emotional change and the aggressive behavior that can not expect.Therefore, need a kind of safe drugs or dietary supplement to promote physical efficiency.
Summary of the invention
The present invention relates to a kind of composition that comprises Quercetin and many other natural products.Said composition can be used for strengthening physical efficiency, promptly improves locomitivity such as speed, intensity, strength, endurance, pliability, agility, equilibrant force, concentrates harmony (focus coordination), reaction time and fatigue recovery ability.
Another aspect of the present invention disclose a kind of contain Quercetin and vitamin B3, vitamin C both or one of composition.In a specific embodiments, said composition further comprises at least a following ingredients: vitamin B1, vitamin B2, vitamin B6 and cobalamin.In another embodiment, it also further comprises at least a following ingredients: caffeine, Epigallo-catechin gallate (EGCG), epicatechin, L-Epicatechin gallate, epigallocatechin and polypheron E.Said composition also can comprise other composition, as vitamin E, CoQ-10, isoflavones, taurine, beet pectin fiber and ginkgo biloba extract.Said composition also can further optionally be added sweetener to improve sugariness, and aforementioned sweetener is for example sorbierite, maltitol, sucrose, high-fructose corn syrup etc.Foregoing also can comprise amino acid, mineral matter, flavoring agent or colouring agent.The leaf of known green tea contains Epigallo-catechin gallate (EGCG), epicatechin, L-Epicatechin gallate, epigallocatechin and polypheron E.Therefore these five kinds of compositions are fit to be provided by green-tea extract.
Composition of the present invention can be dried forms (as powder or tablet) or moisture form (as beverage or syrup), it can be dietary supplement or pharmaceutical preparation, also can be beverage or food, for example tea (as tea beverage or tea bag content), soft drink, fruit juice (as fruit extract or fruit drink), milk, coffee, jelly, ice cream, yogurt, biscuit, cereal based food (cereals), chocolate and snack food (snack bars).Composition of the present invention all can be used for strengthening physical efficiency under any aforementioned forms.Also belong within the scope of the present invention in the application that preparation is used for the treatment of in the medicine of above-mentioned disease as the present composition of active medicine and said composition.
The present invention also discloses a kind of method that strengthens physical efficiency.This method comprises the foregoing to patient's effective dosage of needs.By as the suitably administration said composition that hereinafter described in detail, can strengthen physical efficiency and not have the side effect of medicine performance enhancers such as anabolic steroid.
Along with hereinafter narration provides one or more specific embodiment of the present invention.Other features of the present invention, purpose and advantage will be illustrated by specification and claims.
The specific embodiment
The present invention to small part based on a unexpected discovery, Quercetin, a kind of polyphenoils, and multiple other natural products has collaborative wholesome effect, comprises the physical efficiency of promoting the patient.
For example, the present invention comprises a kind of composition that contains Quercetin, its comprise in vitamin B3, the vitamin C both or one of.Said composition further comprises one or more following ingredients: vitamin B1, vitamin B2, vitamin B6 and cobalamin.Said composition also can further comprise one or more following ingredients: caffeine, Epigallo-catechin gallate (EGCG), epicatechin, L-Epicatechin gallate, epigallocatechin and polypheron E.Green-tea extract is suitable for providing Epigallo-catechin gallate (EGCG), epicatechin, L-Epicatechin gallate, epigallocatechin and polypheron E.
The exemplary-amounts of foregoing composition is: the polypheron E of 0.1-50mg vitamin B1,0.1-150mg vitamin B2,0.1-2000mg vitamin B3,0.1-200mg vitamin B6,5-150 μ g cobalamin, 50-2000mg vitamin C, 50-1500mg caffeine, 20-2000mg Quercetin, 10-500mg Epigallo-catechin gallate (EGCG), 10-500mg epicatechin, 10-500mg L-Epicatechin gallate, 10-500mg epigallocatechin and 10-500mg, wherein aforementioned composition solubilized or be scattered in the 1L aqueous solution.It is identical with the relative scale of aforementioned content that the content of these compositions also can be.Term " Quercetin " refers to quercetin aglycon and quercetin derivative, for example: Quercetin-3-O-glucoside, Quercetin-5-O-glucoside, Quercetin-7-O-glucoside, Quercetin-9-O-glucoside, Quercetin-3-O-rutinoside, Quercetin-3-O-[α-rhamanopyranosyl-(1 → 2)-α-rhamanopyranosyl-(1 → 6)]-β-glucoside, Quercetin-3-O-galactoside, Quercetin-7-O-galactoside, Quercetin-3-O-rhamnoside and Quercetin-7-O-rhamnoside.After digestion, quercetin derivative is converted into quercetin aglycon, a kind of activity form that is absorbed by health.Aforementioned quercetin content refers to the content of Quercetin part in quercetin aglycon or the quercetin derivative.For example: the composition that use every day can be the 1L aqueous solution, and this aqueous solution comprises 1000mg Quercetin, 30mg vitamin B1,85mg vitamin B2,1g vitamin B3,100mg vitamin B6,120 μ g cobalamins, 1200mg vitamin C, 1000IU vitamin E, 1000mg caffeine and comprises the green-tea extract of 120mg Epigallo-catechin gallate (EGCG), 140mg epicatechin, 360mg L-Epicatechin gallate, 360mg epigallocatechin and 120mgpolypheron E.
Said composition also can comprise one or more other active components, as vitamin E, CoQ-10, isoflavones, taurine, beet pectin fiber and ginkgo biloba extract.The exemplary-amounts of these compositions is: the CoQ-10 of 3-1000IU vitamin E, 10-400mg, 20-600mg isoflavones, 10-1000mg taurine, 1-15g beet pectin fiber and 50-500mg ginkgo biloba extract (dry weight).Said composition also can further optionally improve sugariness by adding sweetener, and sweetener for example is sorbierite, maltitol, hydrogenated glucose syrups, hydrogenated starch hydrolysates, high-fructose corn syrup, sucrose, beet sugar, pectin and sucralose.
An example of foregoing is a powder type, and it is applicable to the preparation beverage, as tea or fruit juice.This powder composition also can be used for preparing paste, gel, capsule or tablet.Lactose and cornstarch are used as dilution usually and are used as carrier in tablets in capsule.Generally can add lubricant, as dolomol, to form tablet.
The present composition can be dietary supplement or pharmaceutical preparation.As dietary supplement, said composition can comprise extra nutrients such as mineral matter or amino acid.Said composition also can be beverage or food.Employed in this manual term " beverage " reaches " food " and refers to respectively widely to be used for nutrition is provided and keeps liquid and the solid/semisolid material that animal comprises all kinds of the human normal or growth quickened to animal.The example of beverage products is including but not limited to tea beverage, fruit juice, coffee and milk.The example of food comprises jelly, biscuit, cereal based food, chocolate, snack food, herb extracts, dairy products (as ice cream and yogurt), bean products (as bean curd) and rice product.
Composition of the present invention all can be used for strengthening physical efficiency under any aforementioned forms.As shown in hereinafter embodiment, said composition can be improved the endurance of whole resistant strength, equilibrant force, fatigue recovery power, physical exercise intensity and exercise.Said composition also can be used for treating disease or illness such as arthritis, tumour, diabetes, sex dysfunction, chronic constipation, inflammatory bowel disease; Improve notice or mood; And reduction cholesterol levels or blood pressure.Term " tumour " refers to benign tumour and malignant tumour (as leukaemia, colon cancer, kidney, liver cancer, breast cancer or lung cancer).
Term " improvement ", " treatment " reach " reduction " and point to and need improve its physical efficiency or suffer from one or more aforementioned diseases or have the symptom of one or more diseases or the present composition of the individual effective dosage of tendency, its purpose is to improve physical efficiency or healing, alleviates, alleviates, corrects or improves one or more diseases or illness, or the symptom of one or more diseases or illness or tendency.Term " administration " contains that oral or parenteral route transmits the present composition to the patient with any suitable form, and this suitable form is for example food, beverage, tablet, capsule, supensoid agent and solution.That term " parenteral route " refers to is subcutaneous, in the intracutaneous, intravenous, intramuscular, joint, in the artery, in the synovia, in the breastbone, in the sheath, in the focus or injection in the skull, and different infusion techniques.Term " effective dose " refers to be enough to provide the benefit (for example improving endurance) to health or treats the dosage of the composition of benefit (for example, reducing cholesterol levels or blood pressure).Can carry out reaching in the body in vitro test to determine best method of administration and dosage.
Following specific embodiment should be considered to only be illustrative, and must not be considered to be used to limit other parts disclosed in this invention.Any disclosed content of personage Ke Yiben specification of being familiar with the present technique field does not need further to set forth and can utilize the present invention fullest.All documents cited herein are incorporated herein by reference in full at this.
Embodiment
Embodiment 1
Composition A (1000ml) is by at room temperature mixing the following ingredients preparation: 1000ml orange juice, 1000mg Quercetin, 30mg vitamin B1,85mg vitamin B2,1000mg vitamin B3,100mg vitamin B6,120 μ g cobalamins, 1000IU vitamin E and 1000mg caffeine.All the components derives from Spectrum Laboratory Products, Inc., Gardena, CA; Sigma, St.Louis, MO, and Aldrich, Milwaukee, WI.
(Boston, MA) obtaining weight is the male Spregue-Dawley rat of 240-250g from Charles River Lab.It is divided into the 1st and the 2nd group (5 every group).The 2nd group rat provides foregoing by irritating the food mode in the stomach, and every day, dosage was 8ml/ rat (30ml/Kg body weight), continued 48 days.The 1st group rat only provides water.
, get blood by eye socket and collect blood sample and measure various blood parameters after 0,14,28 and 42 days in administration according to standard method from rat.The results are summarized in down in tabulation one and the table two.
Table one composition A is in the influence of rat blood parameter
0 day 14 days 28 days 42 days
Parameter Term of reference The 1st group The 2nd group The 1st group The 2nd group The 1st group The 2nd group The 1st group The 2nd group
??WBC ??9.4-14.9 ??(THSN/UL) ??17.22 ??15.04 ??17.34 ??16.50 ??18.76 ??16.90 ??17.66 ??14.20
??RBC ??6.2-9.0 ??(MILL/UL) ??6.09 ??5.94 ??6.63 ??6.60 ??7.43 ??7.20 ??7.99 ??7.72
??Hb ??13.4-16.4 ??(GM/DL) ??12.46 ??12.38 ??14.24 ??14.40 ??15.32 ??15.02 ??15.86 ??15.18
Hematocrit ??40.0-49.0 ??(％) ??37.80 ??37.44 ??42.30 ??43.26 ??45.56 ??45.00 ??47.04 ??45.86
??MCV ??52.0-66.0 ??(FL) ??62.20 ??63.20 ??63.80 ??65.40 ??61.60 ??62.60 ??58.80 ??59.40
??MCH ??17.7-19.1 ??(PICO?GM) ??20.46 ??20.84 ??21.50 ??21.82 ??20.68 ??20.86 ??19.88 ??19.72
??MCHC ??32.0-33.5 ??(％) ??32.96 ??33.00 ??33.64 ??33.26 ??33.66 ??33.38 ??33.72 ??33.14
Blood platelet ??780-1400 ??(THSN/UL) ??956.00 ??965.00 ??1084.60 ??1158.80 ??1078.40 ??1076.60 ??967.00 ??962.80
??BANDS ??0.00-0.06 ??(THSN/UL) ??0.00 ??0.00 ??0.00 ??0.00 ??0.00 ??0.00 ??0.00 ??0.00
The segmentation neutrocyte ??0.58-6.30 ??(THSN/UL) ??4.44 ??4.78 ??3.34 ??3.59 ??3.41 ??3.33 ??3.27 ??3.60
Lymphocyte ??3.78-14.9 ??(THSN/UL) ??10.07 ??7.84 ??12.10 ??11.02 ??13.52 ??11.99 ??12.78 ??9.37
Monocyte ??0.02-1.20 ??(THSN/UL) ??3.43 ??2.15 ??1.67 ??1.67 ??1.49 ??1.30 ??1.24 ??1.03
Eosinophil ??0.00-0.01 ??(THSN/UL) ??0.54 ??0.16 ??0.11 ??0.10 ??0.17 ??0.13 ??0.20 ??0.10
Basophilic granulocyte ??0.00-0.00 ??(THSN/UL) ??0.14 ??0.11 ??0.12 ??0.12 ??0.17 ??0.15 ??0.16 ??0.09
ATL ??0.00-0.00 ??(THSN/UL) ??0.02 ??0.00 ??0.00 ??0.00 ??0.00 ??0.00 ??0.00 ??0.00
Metamylocyte ??0.00-0.00 ??(THSN/UL) ??0.00 ??0.00 ??0.00 ??0.00 ??0.00 ??0.00 ??0.00 ??0.00
Myelocyte ??0.00-0.00 ??(THSN/UL) ??0.00 ??0.00 ??0.00 ??0.00 ??0.00 ??0.00 ??0.00 ??0.00
??NRBC/100 ??WBC ??0-0 ??(/100WBC) ??0.60 ??0.40 ??0.00 ??0.00 ??0.00 ??0.00 ??0.00 ??0.00
Granulophilocyte ??0.1-4.0(％) ??1 ??1 ??2.62 ??5.74 ??3.30 ??5.90 ??4.78 ??6.58
Annotate: WBC: leucocyte
RBC: red blood cell
Hb: hemoglobin
MCV: average hematocrit
MCH: the amount of hemoglobin in each red blood cell
MCHC: mean cell hemoglobin concentration
BANDS: jejune neutrophils (premature neutrophil)
NRBC: erythroblast counting
THSN/UL：1,000/ul
MILL/UL：1,000,000/ul
GM/DL：g/dl
FL: thousand part per trillion liters
PICO GM: part per trillion gram
Table two composition A is for the influence of rat granulophilocyte level
Group Term of reference (%) Day The granulophilocyte level of every rat On average ??SD
??1# ??2# ??3# ??4# ??5#
??1 ??0.1-4.0 ??14 ??2.9 ??2.9 ??2 ??4.9 ??4.4 ??2.62 ??0.96
??2 ??0.1-4.0 ??14 ??5.8 ??4.9 ??7.5 ??5.8 ??4.7 ??5.74 ??2.15
??1 ??0.1-4.0 ??28 ??3.1 ??2.2 ??2.2 ??7.2 ??6.8 ??3.30 ??2.5
??2 ??0.1-4.0 ??28 ??4.8 ??6.5 ??5.4 ??5.5 ??7.3 ??5.90 ??1.3
??1 ??0.1-4.0 ??42 ??4.8 ??9.2 ??9 ??5.5 ??5.4 ??4.78 ??2.14
??2 ??0.1-4.0 ??42 ??7.5 ??6.2 ??6.1 ??6.4 ??6.7 ??6.58 ??0.16
Annotate: the SD=standard deviation
Shown in table one and table two, the granulophilocyte level of the rat of administration composition B (the 2nd group) is higher than the granulophilocyte level of the rat that gives water (the 1st group).For example, at the 42nd day, the average granulophilocyte level (6.58%) of the 2nd group of rat was higher than the granulophilocyte level (4.78%) 37.7% of the 1st group of rat.On the other hand, other blood parameters of two groups of rats is not significant different.Reference table one.These results show that composition A can increase the granulophilocyte level but not influence other blood parameters.Granulophilocyte is a kind of immature, seedless red blood cell (RBCs).The increase of granulophilocyte level and other blood parameters do not change, and show that composition A can improve male dogs.
At experimental session, monitor the body weight of rat every day.There is not the difference on the statistics between two groups.
Embodiment 2
Composition B (1000ml) is by at room temperature mixing the following ingredients preparation: the polypheron E of 1000ml orange juice, 1000mg Quercetin, 30mg vitamin B1,85mg vitamin B2,1000mg vitamin B3,100mg vitamin B6,120 μ g cobalamins, 1000IU vitamin E and 1000mg caffeine, 500mg Epigallo-catechin gallate (EGCG), 500mg epicatechin, 500mg catechin and gallate, 500mg epigallocatechin and 500mg.
With 10 weight is that the male Spregue-Dawley rat of 240-250g is divided into the 1st and the 2nd group (5 every group).The 2nd group rat provides composition B by irritating the food mode in the stomach, and every day, dosage was the 14ml/kg body weight, continued 95 days.The 1st group rat only gives water.
Behind the administration composition the 92nd day, every rat on the Rota-Rod treadmill, train (Model 57750, Stoelting Co., Wood dale is Illinois) more than 2 hours.Extra training was after 20 minutes at the 95th day, every rat is placed on the treadmill walks.Write down every rat on treadmill from running to the time of falling down, and obtain the average travel time of the 1st group and the 2nd group rat.Repeat this experiment 3 times (" test A ", " test b " reach " test C ").Experimental result is summarized in table three.
The effect of table three composition B
Group Time on the Rota-Rod treadmill (minute)
The 1st group Test A Test b Test C
??#1 ??2.36 ??13.11 ??23.33
??#2 ??10.69 ??16.02 ??44.21
??#3 ??19.02 ??15.46 ??66.90
??#4 ??2.99 ??16.67 ??16.09
??#5 ??1.34 ??3.41 ??7.82
On average ??7.28 ??12.93 ??31.67
??SE ??3.37 ??2.45 ??10.68
The 2nd group
??#1 ??6.54 ??61.95 ??80.40
??#2 ??16.16 ??21.54 ??41.73
??#3 ??6.91 ??23.83 ??90.47
??#4 ??24.19 ??20.42 ??202.82
??#5 ??32.58 ??15.37 ??67.44
On average ??17.28 ??28.62 ??96.57
??SE ??5.03 ??8.45 ??27.79
Annotate: the SE=standard error
As shown in Table 3, when Therapy lasted is carried out, the time that rat begins trick motion and can walk on treadmill and grow.In all tests, the time that the rat of administration composition B walks on treadmill is the rat length of administration composition B more not.This result shows that composition B can strengthen the physical efficiency of rat.During 95 days of administration, monitor the body weight of rat every day.Difference on the statistics does not appear between the 1st group and the 2nd group.This result shows that the enhancing of the 2nd group of rat physical efficiency is not to be because the cause that body weight increases.
Other specific embodiments
The disclosed feature of all these specifications all can be united in any form.Feature disclosed in this specification can have, and feature identical, equal or similar purpose replaces.Therefore, unless offer some clarification on, disclosed feature only is an example in series of equivalent or the similar features in all these specifications.
According to the disclosed content of this specification, have the knack of those skilled in the art scholar and can confirm substantive characteristics of the present invention easily for any one, and do not breaking away under its spirit and the scope, can make different changes to the present invention and make it meet different purposes and situation with modification.Therefore, other specific embodiments is also contained in the following claims.

Claims (29)

1, a kind of composition that comprises vitamin B3 and Quercetin.
2, a kind of composition that comprises vitamin C and Quercetin.
3, composition as claimed in claim 2, wherein said composition further comprises vitamin B3.
4, composition as claimed in claim 3, wherein said composition further comprise at least a in vitamin B1, vitamin B2, vitamin B6, cobalamin and the vitamin E.
5, composition as claimed in claim 4, wherein said composition further comprise at least a among caffeine, Epigallo-catechin gallate (EGCG), epicatechin, L-Epicatechin gallate, epigallocatechin and the polypheron E.
6, composition as claimed in claim 4, wherein said composition further comprises green-tea extract, and described green-tea extract comprises at least a among caffeine, Epigallo-catechin gallate (EGCG), epicatechin, L-Epicatechin gallate, epigallocatechin and the polypheron E.
7, composition as claimed in claim 1, wherein said composition are dried forms.
8, composition as claimed in claim 2, wherein said composition are dried forms.
9, composition as claimed in claim 3, wherein said composition are dried forms.
10, composition as claimed in claim 1, wherein said composition are tea, soft drink, fruit juice, milk, coffee, jelly, ice cream, yogurt, biscuit, cereal based food, chocolate or snack food.
11, composition as claimed in claim 2, wherein said composition are tea, soft drink, fruit juice, milk, coffee, jelly, ice cream, yogurt, biscuit, cereal based food, chocolate or snack food.
12, composition as claimed in claim 3, wherein said composition are tea, soft drink, fruit juice, milk, coffee, jelly, ice cream, yogurt, biscuit, cereal based food, chocolate or snack food.
13, composition as claimed in claim 4, wherein said composition are tea, soft drink, fruit juice, milk, coffee, jelly, ice cream, yogurt, biscuit, cereal class, chocolate or snack food.
14, composition as claimed in claim 5, wherein said composition are tea, soft drink, fruit juice, milk, coffee, jelly, ice cream, yogurt, biscuit, cereal based food, chocolate or snack food.
15, composition as claimed in claim 6, wherein said composition are tea, soft drink, fruit juice, milk, coffee, jelly, ice cream, yogurt, biscuit, cereal based food, chocolate or snack food.
16, composition as claimed in claim 1, wherein said composition further comprise at least a in CoQ-10, isoflavones, taurine, beet pectin fiber and the ginkgo biloba extract.
17, composition as claimed in claim 2, wherein said composition further comprise at least a in CoQ-10, isoflavones, taurine, beet pectin fiber and the ginkgo biloba extract.
18, composition as claimed in claim 3, wherein said composition further comprise at least a in CoQ-10, isoflavones, taurine, beet pectin fiber and the ginkgo biloba extract.
19, composition as claimed in claim 4, wherein said composition further comprise at least a in CoQ-10, isoflavones, taurine, beet pectin fiber and the ginkgo biloba extract.
20, composition as claimed in claim 5, wherein said composition further comprise at least a in CoQ-10, isoflavones, taurine, beet pectin fiber and the ginkgo biloba extract.
21, composition as claimed in claim 6, wherein said composition further comprise at least a in CoQ-10, isoflavones, taurine, beet pectin fiber and the ginkgo biloba extract.
22, a kind of method that strengthens physical efficiency, this method comprises the composition as claimed in claim 1 to the individual effective dosage of needs.
23, a kind of method that strengthens physical efficiency, this method comprises the composition as claimed in claim 2 to the individual effective dosage of needs.
24, method as claimed in claim 23, wherein said composition further comprises vitamin B3.
25, method as claimed in claim 24, wherein said composition further comprise at least a in vitamin B1, vitamin B2, vitamin B6, cobalamin and the vitamin E.
26, method as claimed in claim 25, wherein said composition further comprise at least a among caffeine, Epigallo-catechin gallate (EGCG), epicatechin, L-Epicatechin gallate, epigallocatechin and the polypheron E.
27, method as claimed in claim 25, wherein said composition further comprises green-tea extract, and described green-tea extract comprises at least a among caffeine, Epigallo-catechin gallate (EGCG), epicatechin, L-Epicatechin gallate, epigallocatechin and the polypheron E.
28, method as claimed in claim 25, wherein said composition comprises vitamin B1, vitamin B2, vitamin B6, cobalamin and vitamin E.
29, method as claimed in claim 26, wherein said composition comprise caffeine, Epigallo-catechin gallate (EGCG), epicatechin, catechin and gallate, epigallocatechin and polypheron E.
CNA2003801021039A 2002-10-23 2003-10-23 Composition for enhancing physical performance Pending CN1708237A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42098602P 2002-10-23 2002-10-23
US60/420,986 2002-10-23
US10/302,544 2002-11-22

Publications (1)

Publication Number Publication Date
CN1708237A true CN1708237A (en) 2005-12-14

Family

ID=32176659

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB2003801021043A Expired - Fee Related CN100361599C (en) 2002-10-23 2003-10-14 Antioxidative compositions
CNA2003801021039A Pending CN1708237A (en) 2002-10-23 2003-10-23 Composition for enhancing physical performance

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNB2003801021043A Expired - Fee Related CN100361599C (en) 2002-10-23 2003-10-14 Antioxidative compositions

Country Status (3)

Country Link
CN (2) CN100361599C (en)
ES (1) ES2362649T3 (en)
WO (1) WO2004037018A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102218049A (en) * 2011-05-06 2011-10-19 天津艾赛博生物技术有限公司 Anti-ageing medicine or health care food composition and application
CN102469816A (en) * 2009-08-10 2012-05-23 斯托克里-丰康普公司 Method for suspending a flavonoid in a beverage
CN102630779A (en) * 2011-02-14 2012-08-15 三得利控股株式会社 Container-bottled drink for matching with quercetin glycoside
CN102753039A (en) * 2010-01-18 2012-10-24 百事可乐公司 Gel-based compositions and methods of making same
CN103096737A (en) * 2010-09-17 2013-05-08 斯托克里-丰康普公司 Methods of reducing blood lactate concentration
CN107252112A (en) * 2017-06-08 2017-10-17 杭州茗朗生物科技有限公司 A kind of tablet containing EGCG

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2872704B1 (en) * 2004-07-12 2007-11-02 Laurent Schwartz PLURITHERAPY AGAINST CANCER
KR101154616B1 (en) 2004-12-31 2012-06-08 (주)아모레퍼시픽 Composition for promoting production of hyaluronic acid containing Kaempferol and Quercetin
EP1888173A2 (en) * 2005-06-07 2008-02-20 DSMIP Assets B.V. Novel use of (-)-epigallocatechin gallate
JP2007001893A (en) * 2005-06-22 2007-01-11 Ito En Ltd Catechin composition and method for production of the same
JP5371428B2 (en) * 2005-07-29 2013-12-18 ティーマ ファウンデーション Composition for reducing alcohol metabolism and reducing the risk of alcohol-induced diseases
WO2007016953A1 (en) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition for reducing alcohol induced liver cancer risk
WO2007016954A1 (en) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition for reducing drug or alcohol induced breast cancer risk
US8110231B2 (en) 2006-04-10 2012-02-07 Kraft Foods Global Brands Llc Methods for making improved texture cereal bars
EP1961310A1 (en) * 2007-02-01 2008-08-27 DSMIP Assets B.V. Novel use of (-) -epigallocatechin gallate
EP1969954A1 (en) * 2007-02-01 2008-09-17 DSMIP Assets B.V. Sauce containing (-)-epigallocatechin gallate
EP2022344A1 (en) 2007-08-02 2009-02-11 Nestec S.A. Reduction of fatigue as a result of exercise
EP2057905A1 (en) * 2007-11-12 2009-05-13 TIMA Foundation Composition for moderating Triglyceride and Cholesterol Levels
US8680053B2 (en) 2008-07-09 2014-03-25 Quercegen Pharmaceuticals Llc Improving renal function with quercetin-containing compositions
US8772230B2 (en) 2009-06-11 2014-07-08 Dsm Ip Assets B.V. Niacin and/or trigonelline as a muscle stimulant
JP5767452B2 (en) * 2010-09-21 2015-08-19 花王株式会社 Frosted cereal food and method for producing the same
US20130129680A1 (en) * 2011-11-23 2013-05-23 Thomas Christian Lines Method for treating hepatitis c virus infection using quercetin-containing compositions
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
CN104172432A (en) * 2014-07-30 2014-12-03 谢松芬 Passion fruit seed oil antioxidant
CN104997129A (en) * 2015-06-17 2015-10-28 哈尔滨松根堂生物科技有限公司 High-efficient compound food additive rich in active factor and application of additive
CN104982940A (en) * 2015-06-17 2015-10-21 哈尔滨松根堂生物科技有限公司 Compound food additive rich in active factors and application thereof
WO2017070501A1 (en) * 2015-10-23 2017-04-27 Reform Biologics, Llc Excipient compounds for biopolymer formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT407942B (en) * 1997-04-16 2001-07-25 Husz Georg Bela BEVERAGE, CONCENTRATE COMBINATION AND METHOD FOR PRODUCING A BEVERAGE
US6261589B1 (en) * 1999-03-02 2001-07-17 Durk Pearson Dietary supplement nutrient soft drink composition with psychoactive effect
US6299925B1 (en) * 1999-06-29 2001-10-09 Xel Herbaceuticals, Inc. Effervescent green tea extract formulation

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102469816A (en) * 2009-08-10 2012-05-23 斯托克里-丰康普公司 Method for suspending a flavonoid in a beverage
CN102753039A (en) * 2010-01-18 2012-10-24 百事可乐公司 Gel-based compositions and methods of making same
US9414615B2 (en) 2010-01-18 2016-08-16 PepciCo, Inc. Gel-based compositions and methods of making same
CN103096737A (en) * 2010-09-17 2013-05-08 斯托克里-丰康普公司 Methods of reducing blood lactate concentration
CN102630779A (en) * 2011-02-14 2012-08-15 三得利控股株式会社 Container-bottled drink for matching with quercetin glycoside
CN102630779B (en) * 2011-02-14 2015-07-22 三得利食品饮料株式会社 Container-bottled drink for matching with quercetin glycoside
CN102218049A (en) * 2011-05-06 2011-10-19 天津艾赛博生物技术有限公司 Anti-ageing medicine or health care food composition and application
CN107252112A (en) * 2017-06-08 2017-10-17 杭州茗朗生物科技有限公司 A kind of tablet containing EGCG

Also Published As

Publication number Publication date
CN1708234A (en) 2005-12-14
ES2362649T3 (en) 2011-07-08
WO2004037018A1 (en) 2004-05-06
CN100361599C (en) 2008-01-16

Similar Documents

Publication Publication Date Title
CN1708237A (en) Composition for enhancing physical performance
US8318225B2 (en) Composition for enhancing physical performance
AU2010202435A1 (en) Composition for enhancing physical performance
JP2011157366A (en) Composition for enhancing physical performance
EP2255818A1 (en) Oral or enteral composition useful for recovery of physical functions
CN104487074A (en) Method for treating hepatitis c virus infection using quercetin-containing compositions
CN101932318A (en) The compositions that is used for stimulating natural killer cell activity
EP2236147B1 (en) Composition for improving nutritional status, reducing frequency of fever and/or increasing immunocompetence of elderly
EP1714650B1 (en) Arginine-containing compositions for increasing blood flow
JP5294149B2 (en) Glutamine-containing composition for increasing blood flow
US20070167395A1 (en) Compositions and methods for treating diabetes
US20060210606A1 (en) Food for improving clinical conditions capable of lowering the concentration of low-molecular weight nitrogen-containing compounds in blood
JP3568201B1 (en) Health foods and beverages
WO2015190682A1 (en) Composition for growth promotion, containing coumaric acid as active ingredient
JP2008074835A (en) Harmful metal excretion agent, method of using the same, and food supplement
RU2776298C1 (en) Biologically active food additives based on ascorbic acid and stevia extract
KR20070049376A (en) Diet drink composition
Nambiar et al. International Journal of Pharmaceutical & Biological Archives 2010; 1 (2): 261-266
CN101474302A (en) Pharmaceutical composition for reducing blood sugar
CN1788614A (en) Health food and rink containing nucleic acid chitin chitosamine for regulating losing control of tissue and organ
CN101596209A (en) The pharmaceutical composition that is used for blood sugar lowering and blood fat
CN101596210A (en) The pharmaceutical composition that is used for blood sugar lowering and blood fat
CN103405493A (en) Application of black bean and extractive of same in manufacture of preparation for inhibiting expression of hepcidin
CN101590150A (en) The pharmaceutical composition that is used for blood sugar lowering and blood fat

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1086726

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1086726

Country of ref document: HK